A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Trial Profile

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs ADCT 402 (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 22 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Dec 2015 New trial record
    • 05 Dec 2015 According to the ADC Therapeutics media release, FDA granted IND clearance to begin phase I clinical trials with ADCT-402 in hematological tumors.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top